BCYC
Price:
$14.85
Market Cap:
$1.02B
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a...[Read more]
Industry
Biotechnology
IPO Date
2019-05-23
Stock Exchange
NASDAQ
Ticker
BCYC
According to Bicycle Therapeutics plc’s latest financial reports and current stock price. The company's current Enterprise Value is 145.11M. This represents a change of -66.29% compared to the average of 430.53M of the last 4 quarters.
The mean historical Enterprise Value of Bicycle Therapeutics plc over the last ten years is 313.08M. The current 145.11M Enterprise Value has changed 4.53% with respect to the historical average. Over the past ten years (40 quarters), BCYC's Enterprise Value was at its highest in in the December 2021 quarter at 1.36B. The Enterprise Value was at its lowest in in the June 2019 quarter at -34062423.90.
Average
313.08M
Median
182.50M
Minimum
13.93M
Maximum
1.13B
Discovering the peaks and valleys of Bicycle Therapeutics plc Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.50%
Maximum Annual Enterprise Value = 1.13B
Minimum Annual Increase = -85.51%
Minimum Annual Enterprise Value = 13.93M
Year | Enterprise Value | Change |
---|---|---|
2023 | 162.04M | -72.21% |
2022 | 583.13M | -48.45% |
2021 | 1.13B | 406.22% |
2020 | 223.45M | 1.50% |
2019 | 13.93M | -85.51% |
2018 | 96.14M | 4.66% |
2017 | 91.86M | -54.74% |
The current Enterprise Value of Bicycle Therapeutics plc (BCYC) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
625.44M
5-year avg
422.74M
10-year avg
313.08M
Bicycle Therapeutics plc’s Enterprise Value is less than IDEAYA Biosciences, Inc. (1.83B), less than AnaptysBio, Inc. (250.61M), less than MeiraGTx Holdings plc (444.90M), less than Keros Therapeutics, Inc. (168.32M), greater than Homology Medicines, Inc. (-103303255.00), greater than Tenaya Therapeutics, Inc. (133.46M), less than IGM Biosciences, Inc. (382.96M), less than Monte Rosa Therapeutics, Inc. (352.48M), less than Stoke Therapeutics, Inc. (448.16M), less than Merus N.V. (2.47B), greater than Inhibrx Biosciences, Inc. (16.13M), less than immatics biotechnologies GmbH (648.34M), greater than Seer, Inc. (122.73M), less than ORIC Pharmaceuticals, Inc. (534.36M), greater than Anebulo Pharmaceuticals, Inc. (37.75M), less than Cullinan Oncology, Inc. (615.40M), less than C4 Therapeutics, Inc. (278.41M), greater than Adagene Inc. (13.88M), less than Acrivon Therapeutics, Inc. Common Stock (155.36M), less than Mineralys Therapeutics, Inc. (521.35M),
Company | Enterprise Value | Market cap |
---|---|---|
1.83B | $2.21B | |
250.61M | $425.70M | |
444.90M | $481.03M | |
168.32M | $679.71M | |
-103303255.00 | $3.02M | |
133.46M | $127.15M | |
382.96M | $379.98M | |
352.48M | $434.36M | |
448.16M | $595.88M | |
2.47B | $2.90B | |
16.13M | $210.62M | |
648.34M | $827.74M | |
122.73M | $133.85M | |
534.36M | $575.47M | |
37.75M | $39.16M | |
615.40M | $715.03M | |
278.41M | $270.96M | |
13.88M | $88.76M | |
155.36M | $194.76M | |
521.35M | $618.62M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Bicycle Therapeutics plc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Bicycle Therapeutics plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Bicycle Therapeutics plc's Enterprise Value?
What is the highest Enterprise Value for Bicycle Therapeutics plc (BCYC)?
What is the 3-year average Enterprise Value for Bicycle Therapeutics plc (BCYC)?
What is the 5-year average Enterprise Value for Bicycle Therapeutics plc (BCYC)?
How does the current Enterprise Value for Bicycle Therapeutics plc (BCYC) compare to its historical average?